Regulon: R-1760
Regulons
are regulatory units consisting of a coherently expressed set of genes and the associated regulator(s) whose binding site(s) they share.
Regulon Summary
Regulon summary table displays all associated information related to the specific regulon including the number of genes in the regulon, Hazard ratio
, its Regulator
, the Transcriptional Program
that includes the regulon, Drugs that are associated with members of the regulon, together with mechanism of action and class, and enriched hallmarks of cancer if any.
Genes | Cox Hazard Ratio | Regulators | Causal Flows | Transcriptional Programs | Hallmarks |
---|---|---|---|---|---|
6 | 2.56489 | 1 | 5 | Pr-5 | ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
Regulon Genes
List of genes that are included in the regulon. These genes have similar expression profiles in subset of patients and they share common binding motif for the Regulator
of the regulon. Clicking on the gene name will take you to the gene specific page with more details. Please wait while information is collated from several resources after you click.
Entrez ID | EnsEMBL ID | Preferred Name | Uniprot ID |
---|---|---|---|
5743 | ENSG00000073756 | PTGS2 | P35354 |
2355 | ENSG00000075426 | FOSL2 | P15408 |
857 | ENSG00000105974 | CAV1 | A0A024R757 |
53918 | ENSG00000152684 | PELO | Q9BRX2 |
1836 | ENSG00000155850 | SLC26A2 | P50443 |
5271 | ENSG00000166401 | SERPINB8 | A0A024R2B1 |
Regulon Drugs
Name | Approved Symbol | Type | Action Type | Mechanism of Action | Max Trial Phase | Max GBM Phase |
---|---|---|---|---|---|---|
IBUPROFEN | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 4 | 2 |
PIRPROFEN | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 4 | 0 |
PHENYLBUTAZONE | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 4 | 0 |
CIMICOXIB | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase-2 inhibitor | 2 | 0 |
ACETAMINOPHEN | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 4 | 2 |
OXYPHENBUTAZONE | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 4 | 0 |
CELECOXIB | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase-2 inhibitor | 4 | 2 |
MELOXICAM | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase-2 inhibitor | 4 | 0 |
BROMFENAC SODIUM | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 4 | 0 |
ACECLOFENAC | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase-2 inhibitor | 4 | 0 |
OLSALAZINE | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 4 | 0 |
LORNOXICAM | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 4 | 0 |
FLURBIPROFEN | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 4 | 0 |
DIPYRONE | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 4 | 0 |
FENOPROFEN | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 4 | 0 |
APRICOXIB | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase-2 inhibitor | 2 | 0 |
NAPROXEN SODIUM | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 4 | 0 |
DEXKETOPROFEN | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 4 | 0 |
PARECOXIB | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase-2 inhibitor | 4 | 0 |
ASPIRIN | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 4 | 2 |
ESFLURBIPROFEN | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 3 | 0 |
ALOXIPRIN | PTGS2 | Unknown | INHIBITOR | Cyclooxygenase inhibitor | 4 | 0 |
ETORICOXIB | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase-2 inhibitor | 4 | 0 |
INDOPROFEN | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 4 | 0 |
KETOROLAC | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 4 | 0 |
INDOMETHACIN SODIUM | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 4 | 0 |
BENZYDAMINE | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 4 | 0 |
LUMIRACOXIB | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase-2 inhibitor | 4 | 0 |
NAPROXEN | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 4 | 0 |
DICLOFENAC EPOLAMINE | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 4 | 0 |
FENOPROFEN CALCIUM | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 4 | 0 |
MECLOFENAMIC ACID | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 4 | 0 |
OLSALAZINE SODIUM | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 4 | 0 |
APAZONE | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 4 | 0 |
NABUMETONE | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase-2 inhibitor | 4 | 0 |
ROFECOXIB | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase-2 inhibitor | 4 | 0 |
MESALAMINE | PPARG | Small molecule | AGONIST | Peroxisome proliferator-activated receptor gamma agonist | 4 | 0 |
ACEMETACIN | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 4 | 0 |
PARECOXIB SODIUM | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase-2 inhibitor | 4 | 0 |
IBUPROFEN SODIUM | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 4 | 0 |
BALSALAZIDE DISODIUM | PPARG | Small molecule | INHIBITOR | Arachidonate 5-lipoxygenase inhibitor | 4 | 0 |
NEPAFENAC | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 4 | 0 |
DICLOFENAC POTASSIUM | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 4 | 0 |
IBUPROFEN LYSINE | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 4 | 0 |
PIROXICAM | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 4 | 0 |
ETODOLAC | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase-2 inhibitor | 4 | 0 |
SUPROFEN | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 4 | 0 |
SULFASALAZINE | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 4 | 1 |
MECLOFENAMATE SODIUM | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 4 | 0 |
GW-406381 | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase-2 inhibitor | 3 | 0 |
LOXOPROFEN | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 3 | 0 |
DICLOFENAC SODIUM | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 4 | 0 |
BENZYDAMINE HYDROCHLORIDE | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 4 | 0 |
TOLMETIN SODIUM | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 4 | 0 |
KETOROLAC TROMETHAMINE | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 4 | 0 |
DEXIBUPROFEN | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 4 | 0 |
SULINDAC | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 4 | 0 |
KETOPROFEN | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 4 | 0 |
BALSALAZIDE | PPARG | Small molecule | INHIBITOR | Arachidonate 5-lipoxygenase inhibitor | 4 | 0 |
NAPROXCINOD | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 3 | 0 |
TOLMETIN | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 4 | 0 |
DICLOFENAC | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 4 | 0 |
BISMUTH SUBSALICYLATE | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 4 | 0 |
MEFENAMIC ACID | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 4 | 0 |
GLAFENINE | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 4 | 0 |
DIFLUNISAL | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 4 | 0 |
BROMFENAC | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 4 | 0 |
NAPROXEN ETEMESIL | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 2 | 0 |
INDOMETHACIN | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 4 | 0 |
OXAPROZIN | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase inhibitor | 4 | 0 |
IGURATIMOD | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase-2 inhibitor | 3 | 0 |
VALDECOXIB | PTGS2 | Small molecule | INHIBITOR | Cyclooxygenase-2 inhibitor | 4 | 0 |
POLMACOXIB | PTGS2 | Small molecule | INHIBITOR | Carbonic anhydrase I inhibitor | 3 | 0 |
Causal Flows
Causal Flows
are statistically significant links between putative causal events (somatic mutations, copy number variations, chromosomal translocations, etc.) and the activity levels of regulators and regulons. In the causal flow a mutation
may causally activates or deactivates a downstream regulator
which then might up- or down-regulates a regulon
that contains genes with similar expression profiles and binding sites.